Summit Therapeutics SMMT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Summit Therapeutics (SMMT) Core Market Data and Business Metrics
Latest Closing Price
$20.46Price-Earnings Ratio
-66.00Total Outstanding Shares
737.68 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
601 Brickell Key Drive, Miami, FL, 33131
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
---|---|---|---|
2,669,434 Shares | 7.95 | 3/14/2025 | 21,221,508 Shares |
3,100,023 Shares | 6.98 | 2/28/2025 | 21,632,544 Shares |
1,917,704 Shares | 11.19 | 2/14/2025 | 21,449,700 Shares |
2,511,139 Shares | 8.31 | 1/31/2025 | 20,855,847 Shares |
2,411,322 Shares | 8.93 | 1/15/2025 | 21,521,491 Shares |
2,355,857 Shares | 8.46 | 12/31/2024 | 19,939,807 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-205.34 Million |
Net Cash Flow From Financing Activities, Continuing | $381.23 Million |
Net Cash Flow | $33.78 Million |
Net Cash Flow From Operating Activities | $-142.11 Million |
Net Cash Flow From Investing Activities | $-205.34 Million |
Net Cash Flow From Operating Activities, Continuing | $-142.11 Million |
Income Statement
January 1, 2024 to December 31, 2024
Metric | Value |
---|---|
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Revenues | $313,000 |
Income/Loss From Continuing Operations Before Tax | $-221.31 Million |
Basic Average Shares | $718.54 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-221.31 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income
January 1, 2024 to December 31, 2024
Metric | Value |
---|---|
Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income/Loss | $-221.15 Million |
Comprehensive Income/Loss Attributable To Parent | $-221.15 Million |
Other Comprehensive Income/Loss | $-221.15 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
Metric | Value |
---|---|
Noncurrent Assets | $11.81 Million |
Intangible Assets | $0 |
Other Current Liabilities | $25.12 Million |
Fixed Assets | $254,000 |
Equity Attributable To Parent | $388.75 Million |
Assets | $435.56 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |